DDInter298 DDInter178
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Carboplatin (Compound) treats esophageal cancer (Disease)
Carboplatin (Compound) binds GSTM1 (Gene)
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Carboplatin (Compound) causes Venous thrombosis (Side Effect)